AI Article Synopsis
Article Abstract
Labetalol hydrochloride is the prototype drug of a new class of antihypertensive agents that competitively and peripherally blocks both beta- and alpha-adrenergic receptors. It possesses approximately one fourth of the beta-blocking activity of propranolol hydrochloride and one half of the alpha-blocking activity of phentolamine. In humans, the effective beta- to alpha-blocking activity is approximately 7:1. It has been used successfully in oral form to treat patients with mild, moderate, and severe hypertension and in intravenous form to manage hypertensive emergencies. Prominent side effects include orthostatic hypotension and gastrointestinal disturbances. Overall, the drug appears to offer several advantages over pure beta-blocking drugs in some patients and should expand the armamentarium of the practicing physician in the management of the difficult hypertensive patient.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archinte.143.3.485 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unified theory of alpha, mu, and tau rhythms via eigenmodes of brain activity.
Front Comput Neurosci
August 2024
School of Physics, University of Sydney, Sydney, NSW, Australia.
A compact description of the frequency structure and topography of human alpha-band rhythms is obtained by use of the first four brain activity eigenmodes previously derived from corticothalamic neural field theory. Just two eigenmodes that overlap in frequency are found to reproduce the observed topography of the classical alpha rhythm for subjects with a single, occipitally concentrated alpha peak in their electroencephalograms. Alpha frequency splitting and relative amplitudes of double alpha peaks are explored analytically and numerically within this four-mode framework using eigenfunction expansion and perturbation methods.
View Article and Find Full Text PDFThe Role of TNF-α in Alzheimer's Disease: A Narrative Review.
Cells
December 2023
Department of Medicine, Surgery and Neuroscience, University of Siena, Viale Bracci 2, 53100 Siena, Italy.
This review analyzes the role of TNF-α and its increase in biological fluids in mild cognitive impairment, and Alzheimer's disease (AD). The potential inhibition of TNF-α with pharmacological strategies paves the way for preventing AD and improving cognitive function in people at risk for dementia. We conducted a narrative review to characterize the evidence in relation to the involvement of TNF-α in AD and its possible therapeutic inhibition.
View Article and Find Full Text PDFPredictive values of circulating miR-146a and miR-155 for disease activity and clinical response to TNF-α blocking therapy in patients with ankylosing spondylitis.
Int J Rheum Dis
January 2024
Department of Orthopedics, Shanghai LiQun Hospital, Shanghai, China.
Objective: Ankylosing spondylitis is an insidiously progressive and debilitating form of arthritis involving the axial skeleton. MicroRNAs have been reported to act as candidate biomarkers for ankylosing spondylitis diagnosis and progression. The study aimed to assess the roles of circulating miR-146a and miR-155 in ankylosing spondylitis and their prediction to clinical response to TNF-α blocking therapy.
View Article and Find Full Text PDFA TNF-α blocking peptide that reduces NF-κB and MAPK activity for attenuating inflammation.
Bioorg Med Chem
September 2023
School of Medicine, Shanghai University, Shanghai 200444, China; Department of Critical Care Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072,China. Electronic address:
Overexpression of tumor necrosis factor-α (TNF-α) is implicated in many inflammatory diseases, including septic shock, hepatitis, asthma, insulin resistance and autoimmune diseases, such as rheumatoid arthritis and Crohn's disease. The TNF-α signaling pathway is a valuable target, and anti-TNF-α drugs are successfully used to treat autoimmune and inflammatory diseases. Here, we study anti-inflammatory activity of an anti-TNF-α peptide (SN1-13, DEFHLELHLYQSW).
View Article and Find Full Text PDFTumor necrosis factor-α (TNF-α) blocking therapy is recommended to treat ankylosing spondylitis for patients who fail to respond to nonsteroidal anti-inflammatory drugs (NSAIDs). Herein, we attempt to dissect whether blood type I and II interferon (IFN) production can be predictive of ankylosing spondylitis progression and treatment response to the tumor necrosis factor inhibitor (TNFi). A total of 50 ankylosing spondylitis patients receiving originator TNFi with a 6-month period were retrospectively analyzed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!